Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, University of Chicago Medicine Partner on Breast Cancer Sequencing Project

NEW YORK (GenomeWeb) – Tempus announced today that it has partnered with the University of Chicago Medicine on a project to improve personalized care for breast cancer patients.

Under the terms of the deal, Tempus will conduct molecular sequencing for about 1,000 breast cancer patients receiving treatment at the school, then analyze the data to generate additional genomic data for a subset of the patients. That information will be used by the University of Chicago Medicine to discover novel genomics patterns that can help determine which patients will respond to particular therapies.

Additional terms were not disclosed.

"We are excited to partner with Tempus on this initiative and eager to support its efforts to build the largest clinically annotated molecular data set in breast cancer," University of Chicago researcher Olufunmilayo Olopade, who is working directly with Tempus under the collaboration, said in a statement. "This could improve clinical care and lead to novel research opportunities."

Tempus has recently inked a number of sequencing deals with hospitals and research institutions including Duke University, the University of Michigan, and the Mayo Clinic.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.